Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (45)
Sung-Soo Park, Seo-Young Goo, Young-Woo Jeon, Seung-Ah Yhang, Seung-Hwan Shin & Chang-Ki Min. (2023) Real-world treatment outcomes of carfilzomib plus dexamethasone in patients with relapsed and/or refractory multiple myeloma, focusing on the impact of trial-fitness: CAtholic REsearch network for Multiple Myeloma study (CAREMM-2203). Journal of Cancer Research and Clinical Oncology 149:18, pages 16279-16291.
Crossref
Crossref
Haris Hatic, Shealeigh Inselman, Jonathan Inselman, Anuhya Kommalapati, Sri Harsha Tella, Jonas Paludo, Urshila Durani, Ronald S. Go & Gaurav Goyal. (2022) Time to first treatment is an independent prognostic factor for Multiple Myeloma (MM). Leukemia Research 123, pages 106966.
Crossref
Crossref
Priscila White, Abigail Cooley, Susan Bal, Kelly Godby, Gayathri Ravi, Deanna Clark, Clare Ubersax, Grant R. Williams, Luciano J. Costa & Smith Giri. (2022) Disparities in clinical trial participation among older adults with multiple myeloma in the United States. Journal of Geriatric Oncology 13:8, pages 1241-1243.
Crossref
Crossref
Kari Lenita Falck Moore, Ingemar Turesson, Anna Genell, Tobias W. Klausen, Dorota Knut-Bojanowska, Louise Redder, Ingigerdur Sverrisdottir, Jonathan Thorsen, Annette J. Vangsted & Cecilie H. Blimark. (2022) Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden. Haematologica 108:6, pages 1640-1651.
Crossref
Crossref
Jiri Minarik, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Tomas Pika, Ludek Pour, Petr Pavlicek, Lubica Harvanova, Lenka Pospisilova, Petra Krhovska, Denisa Novakova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Vladimir Maisnar & Roman Hajek. (2022) Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy. Cancers 14:20, pages 5165.
Crossref
Crossref
Samir Asher, Aikaterini Kazantzi, Fatjon Dekaj, Luke Steventon, Aisha Khatun, Louise Ainley, Annabel McMillan, Neil Rabin, Ashu Wechalekar, Jonathan Sive, Charalampia Kyriakou, Xenofon Papanikolaou, Ke Xu, Shameem Mahmood, Brendan Wisniowski, Lydia Lee, Kwee Yong & Rakesh Popat. (2022) Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma. Haematologica 107:12, pages 2961-2965.
Crossref
Crossref
Ernesto Pérez‐Persona, Itziar Oiartzabal‐Ormategui, Susana Herraez, Carmen Menchaca, Laida Cuevas‐Palomares, Ana Santamaría‐López, Rosana Díez‐Angulo, Diego Robles‐Castro, Carlos de Miguel‐Sánchez, Miren Gabilondo‐Jalón, Carlos Pisón‐Herrero, Ariane Unamunzaga‐Cilaurren, Ana Vega González‐Viñaspre, Laura Salcedo‐Cuesta, Arantza Mendizabal‐Abad & José María Guinea de Castro. (2022) Velcadito: Low dose of bortezomib with melphalan and prednisone for ≥75‐year‐olds newly diagnosed with multiple myeloma. European Journal of Haematology 108:6, pages 532-535.
Crossref
Crossref
Matthew R. LeBlanc, Ashley Leak Bryant, Thomas W. LeBlanc, Qing Yang, Emily Sellars, Cristiana Costa Chase & Sophia K. Smith. (2022) A cross-sectional observational study of health-related quality of life in adults with multiple myeloma. Supportive Care in Cancer 30:6, pages 5239-5248.
Crossref
Crossref
Kathleen Maignan, Lola A. Fashoyin-Aje, Aracelis Z. Torres, Laura L. Fernandes, Thomas Gwise, Shrujal B. Baxi, James P. Roose, Donna R. Rivera, Yuan Li Shen, Paul G. Kluetz & Nicole J. Gormley. (2022) Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data. Blood Cancer Journal 12:4.
Crossref
Crossref
Cecilie Hveding Blimark, Annette Juul Vangsted, Tobias W. Klausen, Henrik Gregersen, Agoston Gyula Szabo, Emil Hermansen, Göran Wålinder, Dorota Knut‐Bojanowska, Chenyang Zang & Ingemar Turesson. (2021) Outcome data from >10 000 multiple myeloma patients in the Danish and Swedish national registries. European Journal of Haematology 108:2, pages 99-108.
Crossref
Crossref
Ernesto Pérez Persona, Itziar Oiartzabal Ormategui, Laida Cuevas Palomares, Ana Santamaría López, Diego Robles de Castro, Carlos Miguel de Sánchez, Miren Gabilondo Jalón, Carlos Pisón Herrero, Ariane Unamunzaga Cilaurren, Ana Vega González de Viñaspre & Jose María Guinea de Castro. (2021) Treatment burden in multiple myeloma according to comorbidity in real life. Annals of Hematology 101:2, pages 437-440.
Crossref
Crossref
Jiri Minarik, Tomas Pika, Jakub Radocha, Alexandra Jungova, Jan Straub, Tomas Jelinek, Ludek Pour, Petr Pavlicek, Martin Mistrik, Lucie Brozova, Petra Krhovska, Katerina Machalkova, Pavel Jindra, Ivan Spicka, Hana Plonkova, Martin Stork, Jaroslav Bacovsky, Lenka Capkova, Michal Sykora, Petr Kessler, Lukas Stejskal, Adriana Heindorfer, Jana Ullrychova, Tomas Skacel, Vladimir Maisnar & Roman Hajek. (2021) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice. BMC Cancer 21:1.
Crossref
Crossref
Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Marveh Dokhi, Eva Kurt, Casper Strandholdt, Mette Klarskov Andersen & Annette Juul Vangsted. (2021) The real-world outcomes of multiple myeloma patients treated with daratumumab. PLOS ONE 16:10, pages e0258487.
Crossref
Crossref
Karen Louise Højholt, Henrik Gregersen, Agoston Gyula Szabo, Tobias Wirenfeldt Klausen, Mette Bøegh Levring, Birgitte Preiss, Carsten Helleberg, Marie Fredslund Breinholt, Emil Hermansen, Lise Mette Rahbek Gjerdrum, Søren Thorgaard Bønløkke, Katrine Nielsen, Eigil Kjeldsen, Katrine Fladeland Iversen, Elena Manuela Teodorescu, Eva Kurt, Casper Strandholdt, Mette Klarskov Andersen & Annette Juul Vangsted. (2021) Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients. Hematological Oncology 39:4, pages 521-528.
Crossref
Crossref
Sandra Michiels, Sandra Tricas-Sauras, Marie Dauvrin, Dominique Bron & Fati Kirakoya-Samadoulougou. (2021) A mixed method study design to explore the adherence of haematological cancer patients to oral anticancer medication in a multilingual and multicultural outpatient setting: The MADESIO protocol. PLOS ONE 16:6, pages e0253526.
Crossref
Crossref
Krystal Bergin, Cameron Wellard, Elizabeth Moore, Zoe McQuilten, Hilary Blacklock, Simon J. Harrison, P. Joy Ho, Tracy King, Hang Quach, Peter Mollee, Patricia Walker, Erica Wood & Andrew Spencer. (2021) The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma Myeloma and Leukemia 21:6, pages e510-e520.
Crossref
Crossref
Roman Hájek, Jiří Minařík, Jan Straub, Luděk Pour, Alexandra Jungova, Jesus G Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits van Rhee, Jorge Vela-Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L Costello, Faith E Davies, Vania TM Hungria, Hans C Lee, Xavier Leleu, Noemi Puig, Robert M Rifkin, Evangelos Terpos, Saad Z Usmani, Katja C Weisel, Jeffrey A Zonder, Magda Bařinová, Matyáš Kuhn, Jiří Šilar, Lenka Čápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren & Vladimír Maisnar. (2021) Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology.
Crossref
Crossref
Matthew LeBlanc, Thomas LeBlanc, Ashley Leak Bryant, Kathryn Pollak, Donald Bailey & Sophia Smith. (2021) A Qualitative Study of the Experiences of Living With Multiple Myeloma. Oncology Nursing Forum 48:2, pages 151-160.
Crossref
Crossref
A. S. Rosenberg, A. Brunson, J. Tuscano, B. A. Jonas, R. Hoeg, T. Wun & T. H. M. Keegan. (2021) Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood Cancer Journal 11:1.
Crossref
Crossref
Tilman Steinmetz, Angela Ernst, Martin Hellmich, Melanie Heinz & Uwe Totzke. (2021) Effectiveness of Long-Term Treatment of Multiple Myeloma in Regular Care: Comparison of a Longitudinal and a Cross-Sectional Analysis Approach. Oncology Research and Treatment 44:12, pages 662-671.
Crossref
Crossref
Miles D. Witham, Eleanor Anderson, Camille Carroll, Paul M. Dark, Kim Down, Alistair S. Hall, Joanna Knee, Rebecca H. Maier, Gail A. Mountain, Gary Nestor, Laurie Oliva, Sarah R. Prowse, Amanda Tortice, James Wason & Lynn Rochester. (2020) Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. Trials 21:1.
Crossref
Crossref
Ansh Mehta, Nathanael Fillmore, Saurabh Dahiya, Anita D'Souza, John Sweetenham & Ankit Kansagra. (2020) Reporting of race and ethnicity at an international haematology conference. British Journal of Haematology 191:5.
Crossref
Crossref
Pashna N. Munshi, David Vesole, Artur Jurczyszyn, Jan Maciej Zaucha, Andrew St. Martin, Omar Davila, Vaibhav Agrawal, Sherif M. Badawy, Minoo Battiwalla, Saurabh Chhabra, Edward Copelan, Mohamed A. Kharfan‐Dabaja, Nosha Farhadfar, Siddhartha Ganguly, Shahrukh Hashmi, Maxwell M. Krem, Hillard M. Lazarus, Ehsan Malek, Kenneth Meehan, Hemant S. Murthy, Taiga Nishihori, Rebecca L. Olin, Richard F. Olsson, Jeffrey Schriber, Sachiko Seo, Gunjan Shah, Melhem Solh, Jason Tay, Shaji Kumar, Muzaffar H. Qazilbash, Nina Shah, Parameswaran N. Hari & Anita D’Souza. (2020) Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 126:23, pages 5077-5087.
Crossref
Crossref
Øystein O. Langseth, Tor Å. Myklebust, Tom B. Johannesen, Øyvind Hjertner & Anders Waage. (2020) Incidence and survival of multiple myeloma: a population‐based study of 10 524 patients diagnosed 1982–2017. British Journal of Haematology 191:3, pages 418-425.
Crossref
Crossref
Ghulam Rehman Mohyuddin, Kelly Koehn, Luciano Costa, Shaji K Kumar & Brian McClune. (2020) Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. The Lancet Haematology 7:10, pages e704-e706.
Crossref
Crossref
Zhe He, Xiang Tang, Xi Yang, Yi Guo, Thomas J. George, Neil Charness, Kelsa Bartley Quan Hem, William Hogan & Jiang Bian. (2020) Clinical Trial Generalizability Assessment in the Big Data Era: A Review. Clinical and Translational Science 13:4, pages 675-684.
Crossref
Crossref
Matthew R. LeBlanc, Rachel Hirschey, Ashley Leak Bryant, Thomas W. LeBlanc & Sophia K. Smith. (2019) How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. Quality of Life Research 29:6, pages 1419-1431.
Crossref
Crossref
Maximilian Mair, Christian Straka, Thomas Buratti, Martina Tauber, Manfred Mitterer & Dominic Fong. (2020) Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis. Annals of Hematology 99:5, pages 1031-1040.
Crossref
Crossref
H. Tilman Steinmetz, Moushmi Singh, Andrea Lebioda, Sebastian Gonzalez-McQuire, Achim Rieth, Martina Schoehl & Wolfram Poenisch. (2020) Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany. Oncology Research and Treatment 43:9, pages 449-459.
Crossref
Crossref
Ronan W. Hsieh, Ronald S. Go, Jithma P. Abeykoon, Prashant Kapoor, Shaji K. Kumar, Morie A. Gertz, Francis K. Buadi, Nelson Leung, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Rahma M. Warsame, Angela Dispenzieri, Martha Q. Lacy, Robert A. Kyle, S. Vincent Rajkumar & Jonas Paludo. (2019) Characteristics of long‐term survivors with multiple myeloma: A National Cancer Data Base analysis. Cancer 125:20, pages 3574-3581.
Crossref
Crossref
Caitlin Costello, Faith E Davies, Gordon Cook, Jorge Vela-Ojeda, Jim Omel, Robert M Rifkin, Jesus Berdeja, Noemi Puig, Saad Z Usmani, Katja Weisel, Jeffrey A Zonder, Evangelos Terpos, Andrew Spencer, Xavier Leleu, Mario Boccadoro, Michael A Thompson, Dorothy Romanus, Dawn M Stull & Vania Hungria. (2019) INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncology 15:13, pages 1411-1428.
Crossref
Crossref
Siddhartha Ganguly, Sham Mailankody & Sikander Ailawadhi. (2019) Many Shades of Disparities in Myeloma Care. American Society of Clinical Oncology Educational Book:39, pages 519-529.
Crossref
Crossref
J. Radocha, R. Hájek, L. Brožová, L. Pour, I. Špička, J. Minařík, E. Gregora, A. Jungová, T. Jelínek, A. Heindorfer, M. Sýkora & V. Maisnar. (2018) Simplified novel prognostic score for real-life older adults with multiple myeloma—registry-based analysis. Annals of Hematology 98:4, pages 951-962.
Crossref
Crossref
Aaron S Rosenberg, Ann Brunson, Brian A Jonas, Theresa H M Keegan & Ted Wun. (2019) Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. JNCI: Journal of the National Cancer Institute 111:1, pages 78-85.
Crossref
Crossref
Maria Paula Curado, Max M. Oliveira, Diego R. M. Silva & Dyego L. B. Souza. (2018) Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Medicine 7:5, pages 2101-2108.
Crossref
Crossref
E. Dianne Pulte, Lei Nie, Nicole Gormley, Kirsten B. Goldberg, Amy McKee, Ann Farrell & Richard Pazdur. (2018) Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications. Blood Advances 2:2, pages 116-119.
Crossref
Crossref
Ola Landgren. (2017) Racial/ethnic disparities: need more work!. Blood 130:15, pages 1685-1686.
Crossref
Crossref
Kedar Kirtane & Stephanie J. Lee. (2017) Racial and ethnic disparities in hematologic malignancies. Blood 130:15, pages 1699-1705.
Crossref
Crossref
Jeffrey R. Schriber, Parameswaran N. Hari, Kwang Woo Ahn, Mingwei Fei, Luciano J. Costa, Mohamad A. Kharfan‐Dabaja, Miguel Angel‐Diaz, Robert P. Gale, Siddharatha Ganguly, Saulius K. Girnius, Shahrukh Hashmi, Attaphol Pawarode, David H. Vesole, Peter H. Wiernik, Baldeep M. Wirk, David I. Marks, Taiga Nishihori, Richard F. Olsson, Saad Z. Usmani, Tomer M. Mark, Yago L. Nieto & Anita D'Souza. (2017) Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer 123:16, pages 3141-3149.
Crossref
Crossref
Sikander Ailawadhi, Kirtipal Bhatia, Sonikpreet Aulakh, Zahara Meghji & Asher Chanan-Khan. (2017) Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet?. Current Hematologic Malignancy Reports 12:4, pages 309-316.
Crossref
Crossref
Maximilian Merz, Lenka Kellermann, Wolfram Poenisch, Hans-Joachim Tischler, Joern Kohnke, Wolfgang Knauf & Hartmut Goldschmidt. (2017) Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. Annals of Hematology 96:6, pages 987-993.
Crossref
Crossref
Nitya Nathwani & Tanya M. Wildes. (2017) Study design for vulnerable older adults with multiple myeloma. Journal of Geriatric Oncology 8:3, pages 162-164.
Crossref
Crossref
Luciano J. Costa, Ilene K. BrillJames OmelKelly GodbyShaji K. Kumar & Elizabeth E. Brown. (2017) Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Advances 1:4, pages 282-287.
Crossref
Crossref
Dickran Kazandjian. (2016) Multiple myeloma epidemiology and survival: A unique malignancy. Seminars in Oncology 43:6, pages 676-681.
Crossref
Crossref
Charles A. Clark, Robert F. Cornell, Emma C. Scott, Jae Chung & Luciano J. Costa. (2016) Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making. American Journal of Hematology 91:10, pages 1044-1051.
Crossref
Crossref